Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences [Yahoo! Finance]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Longwood Boston CEO Conference Date: Monday, October 28, 2024 Time: 11:10 AM ET Title: Expanding Platform Potential Format: Panel Guggenheim Inaugural Healthcare Conference Date: Monday, November 11, 2024 Time: 3:00 PM ET Location: InterContinental Boston Format: Fireside Chat Webcast Link: Register Here A live webcast for the Guggenheim Inaugural Healthcare Conference will also be accessible on Precision's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com . An archived replay of the webcasts will be available for approximately 30 days following the event. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enabl
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing ProgramsBusiness Wire
- Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Precision BioSciences, Inc. (NASDAQ: DTIL) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $34.00 price target on the stock.MarketBeat
- Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire
- iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire
DTIL
Earnings
- 11/4/24 - Miss
DTIL
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- DTIL's page on the SEC website